ZYN002 – CBD Gel ZYN002 is the first and only pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is being developed for patients suffering from FXS, ASD in pediatric patients, 22q, and a heterogeneous group of rare and ultra-rare epilepsies … Pivotal Fragile X Trial Begins Testing ZYN002, Zynerba's ZYN002 is administered as a gel through the skin once or twice daily, allowing its direct absorption from the skin into the blood. This direct formulation allows patients to use lower doses than a pill, and minimizes the risk of side effects. Zynerba Reports Positive Results for ZYN002 Cannabidiol Gel in Zynerba Pharmaceutical today announced additional results from Phase 1 randomized, double-blind, placebo-controlled single and multiple ascending dose studies of ZYN002 cannabidiol (CBD) gel. Zynerba CBD Gel Clinical Trial for Fragile X Overview - YouTube 27.06.2019 · Dr. Craig Erickson of Cincinnati Children's Hospital Medical Center gives us an overview of the CONNECT-FX Fragile X clinical trial of CBD gel. CONNECT-FX (Clinical Study of Cannabidiol (CBD) in
Zynerba (NASDAQ:ZYNE) Starts Clinical Trial of ZYN002 CBD Gel in
The Investor Relations website contains information about Zynerba Pharmaceuticals Inc's business for stockholders, potential investors, and financial analysts. Zynerba Pharmaceuticals - Research Reports by Finpedia ZYN002 – CBD Transdermal Gel. ZYN002 is the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery (see Figure 1), and is patent protected through 2030. Figure 1 — Chemical structure and transdermal gel delivery of CBD.
Zynerba CBD Gel Clinical Trial for Fragile X Overview - YouTube
14 Jan 2019 Fragile X Syndrome, Drug: ZYN002 - CBD Transdermal Gel, Phase 2 and tolerability of CBD administered as ZYN002, a transdermal gel, 22 Jan 2020 Overview; Clinical Development Timelines. Cannabinoid Science Overview. Product Candidates. ZYN002 – CBD Transdermal Gel; Intellectual 12 Nov 2019 part of an expanding intellectual property portfolio covering the Company's transdermal CBD product candidate, Zygel™ (ZYN002 CBD gel). This study will evaluate the efficacy and safety of ZYN002, a clear cannabidiol (CBD) gel that can be applied to the skin (called transdermal application) twice a 6 Aug 2019 This trial evaluated ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS). The results of the trial 22 Feb 2019 Zynerba Pharmaceuticals' quest for CBD gel to treat Fragile X syndrome which will evaluate the potency and safety of ZYN002, a CBD gel,
Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of
This study evaluated safety and efficacy of ZYN002 (trans- dermal synthetic CBD gel) for the treatment of knee pain due to OA in adults. Methods: A Phase 2A, 6 May 2019 lead development candidate Zygel™ (ZYN002 CBD gel) for treatment of behavioral symptoms associated with Fragile X Syndrome (FXS). 31 Jul 2019 CBD is derived from the hemp plant, which falls under the cannabis the Company's lead development candidate Zygel™ (ZYN002 CBD gel) Learn more about Cannabidiol (Cbd) uses, effectiveness, possible side effects, interactions, dosage, user ratings and products that contain Cannabidiol (Cbd)